1e
19
1
49
2
2
18
1b
1d
18
34
45
1d
2 29
1d
25
Steven E. Arnold, M.D.
78
45
Emeritus Professor of Psychiatry
28
8b
3
61
Associate Director, Institute on Aging, University of Pennsylvania, Philadelphia, PA
84
Associate Director, Alzheimer Disease Core Center, University of Pennsylvania
79
Director, Geriatric Psychiatry Section, University of Pennsylvania
a9
Director, Penn Memory Center/Alzheimer's Disease Center Clincal Core, University of Pennsylvania, Philadelphia, PA
11
Department: Psychiatry
4
1
b
1d
46
Contact information
40
4
3
3
1d
40
Penn Memory Center
1c 3615 Chestnut Street
c or
30 2205 Translational Research Laboratories
38 123 South 31st Street
Philadelphia, PA 19104
26
1c 3615 Chestnut Street
c or
30 2205 Translational Research Laboratories
38 123 South 31st Street
Philadelphia, PA 19104
30
Office: (215) 349-8225
34 Fax: (215) 349-8540
34 Lab: (215) 573-2840
18
99
34 Fax: (215) 349-8540
34 Lab: (215) 573-2840
18
Email:
steven.arnold@uphs.upenn.edu
12
steven.arnold@uphs.upenn.edu
18
Publications
23 a
3
2
29
4
b
1f
23 a
13
Education:
21 9 M.D. 15 (Medicine) c
2a Boston University, 1983.
21 9 B.A. 28 (Medical Science, Philosophy) c
27 Boston University, Summa cum laude 16 , 1983.
c
3
3
3
3
8b
Permanent link21 9 M.D. 15 (Medicine) c
2a Boston University, 1983.
21 9 B.A. 28 (Medical Science, Philosophy) c
27 Boston University, Summa cum laude 16 , 1983.
c
2 29
21
1e
1d
24
5e
65
1a 29
27
Description of Research Expertise
e1 schizophrenia; neuropsychiatry; cognition in aging and neurodegenerative dementias; clinicopathological correlation studies; postmortem research; cellular and molecular neuropathology; quantitative microscopy.65
Description of Clinical Expertise
107 Evaluation, diagnosis and medical management of complex neuropsychiatric disorders; Alzheimer's disease and other neurodegenerative dementias;traumatic brain injury; cognitive, mood, and behavioral complications of neurological illness and injury.1a 29
23
341 Naylor, M.D., Karlawish, J.H., Arnold, S.E., Khachaturian, A.S., Khachaturian, Z.S., Lee, V.M., Baumgart, M., Banerjee, S., Beck, C., Blennow, K., Brookmeyer, R., Brunden, K.R., Buckwalter, K.C., Comer,M., Covinsky, K., Feinberg, L.F., Frisoni, G., Green, C., Guimaraes, R.M., Gwyther, L.P., Hefti, F.F., Hutton, M., Kawas, C., Kent, D.M., Kuller, L., Langa, K.M., Mahley, R.W., Maslow, K., Masters, C.L., Meier, D.E., Neumann, P.J., Paul, S.M., Peterson, R.C., Sager, M.A., Sano, M., Schenk, D., Soares, H., Sperling, R.A., Stahl, S.M., vanDeerlin, V., Stern, Y., Weir, D., Wolk, D.A., Trojanowski, J.Q.: Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimers Dement 8(5): 445-52, Sep 2012.
149 Wolk, D.A., Zhang, Z., Boudhar, S., Clark, C.M., Pontecorvo, M.J., Arnold, S.E.: Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 83(9): 923-6, Sep 2012.
18b Irwin, D. J., McMillan, C.T., Toledo, J.B., Arnold, S.E., Shaw, L.M., Wang, L.S., VanDeerlin, V., Lee, V.M., Trojanowski, J.Q., Grossman, M.: Comparison of cerebrospinal fluid levels of tau and ab 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 69(8): 1018-25, Aug 2012.
217 Hu, W.T., Holtzman, D.M., Fagan, A.M., Shaw, L.M., Perrin, R., Arnold, S.E., Grossman, M., Xiong, C., Craig-Schapiro, R., Clark, C.M., Pickering, E., Kuhn, M., Chen, Y., VanDeerlin, V.M., McClusky, L., Elman, L., Karlawish, J., Chen-Plotkin, A., Hurtig, H.I., Siderowf, A., Swenson, F., Lee, V.M., Morris, J.C., Trojanowski, J.Q., Soares, H.: Plasma multianalyte profiling in mild cognitive impairment and Alzheimer's disease. Neurology 79(9): 897-905, Aug 2012.
12b Zhang, Q., Stafford, R.B., Wang, Z., Arnold, S.E., Wolk, D.A., Detre, J.A.: Microvascular Perfusion Based on Arterial Spin Labeled Perfusion MRI as a Measure of Vascular Risk in Alzheimer's Disease. J Alzheimers Dis. Aug 2012.
141 Toledo, J.B., Brettschneider, J., Grossman, M., Arnold, S.E., Hu, W.T., Xie, S.X., Lee, V.M., Shaw, L.M., Trojanowski, J.Q.: CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 124(1): 23-35, Jul 2012.
18a Farlow, M., Arnold, S.E., vanDyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Dean, R.A., Gonzales, C., Sethuraman, G., DeMattos, R.B., Mohs, R., Paul, S.M., Siemers, E.R.: Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8(4): 261-71, Jul 2012.
120 Newberg, A.B., Arnold, S.E., Wintering, N., Rovner, B.W., Alavi, A.: Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 53(6): 902-7, Jun 2012.
1f1 Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., DeFelice, F.G.: An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimeer's disease-associated Ab oligomers. J Clin Invest 122(4): 1339-53, April 2012.
2c
7
1d
1f
Selected Publications
116 DeJesus-Cortes, H.J., Nogueras-Ortiz, C.J., Gearing, M., Arnold, S.E., Vega, I.E.: Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration. Neuroreport 23(16): 942-946, Nov 2012.341 Naylor, M.D., Karlawish, J.H., Arnold, S.E., Khachaturian, A.S., Khachaturian, Z.S., Lee, V.M., Baumgart, M., Banerjee, S., Beck, C., Blennow, K., Brookmeyer, R., Brunden, K.R., Buckwalter, K.C., Comer,M., Covinsky, K., Feinberg, L.F., Frisoni, G., Green, C., Guimaraes, R.M., Gwyther, L.P., Hefti, F.F., Hutton, M., Kawas, C., Kent, D.M., Kuller, L., Langa, K.M., Mahley, R.W., Maslow, K., Masters, C.L., Meier, D.E., Neumann, P.J., Paul, S.M., Peterson, R.C., Sager, M.A., Sano, M., Schenk, D., Soares, H., Sperling, R.A., Stahl, S.M., vanDeerlin, V., Stern, Y., Weir, D., Wolk, D.A., Trojanowski, J.Q.: Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimers Dement 8(5): 445-52, Sep 2012.
149 Wolk, D.A., Zhang, Z., Boudhar, S., Clark, C.M., Pontecorvo, M.J., Arnold, S.E.: Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 83(9): 923-6, Sep 2012.
18b Irwin, D. J., McMillan, C.T., Toledo, J.B., Arnold, S.E., Shaw, L.M., Wang, L.S., VanDeerlin, V., Lee, V.M., Trojanowski, J.Q., Grossman, M.: Comparison of cerebrospinal fluid levels of tau and ab 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 69(8): 1018-25, Aug 2012.
217 Hu, W.T., Holtzman, D.M., Fagan, A.M., Shaw, L.M., Perrin, R., Arnold, S.E., Grossman, M., Xiong, C., Craig-Schapiro, R., Clark, C.M., Pickering, E., Kuhn, M., Chen, Y., VanDeerlin, V.M., McClusky, L., Elman, L., Karlawish, J., Chen-Plotkin, A., Hurtig, H.I., Siderowf, A., Swenson, F., Lee, V.M., Morris, J.C., Trojanowski, J.Q., Soares, H.: Plasma multianalyte profiling in mild cognitive impairment and Alzheimer's disease. Neurology 79(9): 897-905, Aug 2012.
12b Zhang, Q., Stafford, R.B., Wang, Z., Arnold, S.E., Wolk, D.A., Detre, J.A.: Microvascular Perfusion Based on Arterial Spin Labeled Perfusion MRI as a Measure of Vascular Risk in Alzheimer's Disease. J Alzheimers Dis. Aug 2012.
141 Toledo, J.B., Brettschneider, J., Grossman, M., Arnold, S.E., Hu, W.T., Xie, S.X., Lee, V.M., Shaw, L.M., Trojanowski, J.Q.: CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 124(1): 23-35, Jul 2012.
18a Farlow, M., Arnold, S.E., vanDyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Dean, R.A., Gonzales, C., Sethuraman, G., DeMattos, R.B., Mohs, R., Paul, S.M., Siemers, E.R.: Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8(4): 261-71, Jul 2012.
120 Newberg, A.B., Arnold, S.E., Wintering, N., Rovner, B.W., Alavi, A.: Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 53(6): 902-7, Jun 2012.
1f1 Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., DeFelice, F.G.: An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimeer's disease-associated Ab oligomers. J Clin Invest 122(4): 1339-53, April 2012.
2c